The Challenge of Data Collection

Another vital challenge with outcomes-based pricing is reliable data collection. To measure outcomes accurately, it is essential to collect data not only during the clinical trial phase but also during the post-approval phase. This data collection requires significant investments in infrastructure, technology, and personnel, which can be challenging for smaller or newer companies. Moreover, there is often a lag between data collection and the issuance of payment, which may cause cash flow issues for manufacturers.

The Challenge of Payer Engagement

For outcomes-based pricing to succeed, manufacturer-payor collaboration is critical. It is essential to establish clear agreements between the payor and the manufacturer regarding outcome measures, data collection, and pricing methodology. However, payors may be hesitant to adopt outcomes-based pricing due to concerns about administrative burdens, data access, and pricing transparency. Therefore, manufacturers must engage with payors early and transparently to ensure broad adoption of this pricing model.

The Challenge of Regulatory Expectations

Medicine Regulators, such as the US Federal Drug Administration (FDA), may have specific expectations for the clinical trial design and outcome measurement for products using outcomes-based pricing. For example, the FDA may ask for detailed plans for data collection and analysis before approving a clinical trial. This level of scrutiny can be challenging for manufacturers, who must balance the expectations of Regulators with the need to innovate new medicines to meet unmet medical needs.

The Challenge of Pricing Uncertainty

One of the primary challenges of outcomes-based pricing is the uncertainty regarding the ultimate price paid for the medicine. This pricing uncertainty can be challenging for manufacturers, who may have significant investments in research and development and are seeking a return on that investment. The uncertainty may also discourage new entrants to the market who are uncertain about the potential revenue for their product. Thus, it is essential to have clear and transparent pathways for price negotiation and to ensure that manufacturers are appropriately compensated for their products.

Whilst outcomes-based pricing would seem to be burdensome, if structured correctly, it is an innovative solution to the conundrum of pricing medicines that effectively reflect their value. While this pricing model has several challenges, including defining outcomes, data collection, payor engagement, pricing uncertainty, and regulatory expectations, these are surmountable with proper planning, collaboration, and stakeholder engagement. When implemented correctly, outcomes-based pricing holds the potential to revolutionise the way we price medicines, ensuring that patients receive access to the most effective treatment at an affordable price.

Our team of legal consultants are well versed in structuring outcomes based pricing models, and contract development, which are transferable into the commercial setting, ensuring the data collection burden is seamlessly integrated.

If you would like to discuss how we could help you, please do  book a no obligation meeting:

meeting booking or email us:

We would be delighted to support you.